Analysts forecast explosive growth ahead for AI in healthcare, with MarketsandMarkets projecting the market to surge past $110 billion by 2030 on a 38.6% compound annual growth rate. Accenture goes ...

Novo has a strong balance sheet and ended 2024 with about DKK 26 billion in cash and marketable securities and DKK 103 billion of debt (following the acquisition of Catalent manufacturing sites in ...

Asian shares fell Monday and U.S. futures and the dollar weakened after Moody’sRatings downgraded the sovereign credit rating ...

Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...

Novo Nordisk A/S has generally positive cash flows and wider gross margins than its peer group. Additionally, the company's ...

Market Domination host Josh Lipton and guest host, Bullseye American Ingenuity Fund Portfolio Manager Adam Johnson, focus in ...

Novo Nordisk (NVO) stock fell after announcing that CEO Lars Fruergaard Jørgensen will step down. BMO Capital Markets ...

(Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the ...

The pharmaceutical giant Novo Nordisk announced on Friday, May 16, 2025, that CEO Lars Fruergaard Jørgensen is stepping down amid mounting challenges for the obesity drug maker. The sudden leadership ...

Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering and its CEO is out. Novo Nordisk rode Ozempic's success to becoming Europe's top company. Now it's faltering ...

Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...

Novo Nordisk and Septerna enter $2.2 billion deal to develop oral small-molecule therapies targeting obesity, diabetes, and ...